Welcome to our dedicated page for Redhill Biopharma news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharma stock.
RedHill Biopharma Ltd. develops and commercializes specialty biopharmaceutical products focused on gastrointestinal diseases, infectious diseases and oncology. Its recurring news includes U.S. commercialization activity for Talicia, an FDA-approved all-in-one rifabutin-based therapy for H. pylori infection, as well as updates on joint commercialization through Talicia Holdings Inc.
Company updates also cover clinical and preclinical development across RedHill’s pipeline, including RHB-204 for MAP-related Crohn’s disease research, RHB-102 (Bekinda) for gastrointestinal and oncology-support indications, and opaganib in oncology models and related clinical research. Additional recurring themes include regulatory disclosures, intellectual property, capital-structure matters, governance actions and operating or financial results for the foreign issuer’s ADSs.
RedHill Biopharma (Nasdaq: RDHL) announced a transformational deal with Ferring Pharmaceuticals, acquiring exclusive global commercialization rights to Rebyota and exclusive U.S. rights to Clenpiq. According to RedHill, the products generated approximately $37.5 million in U.S. net sales in 2025 ($16.9 million Rebyota, $20.6 million Clenpiq).
Under the agreement, RedHill pays Ferring a $12 million upfront fee, fully funded from the previously announced $18 million Talicia divestiture, plus potential milestones and tiered royalties. Ferring retains Rebyota manufacturing and will supply product for the agreement term. Rebyota, FDA-approved in 2022 and Health Canada-approved in 2025, has Breakthrough Therapy and Orphan Drug designations with protections that could run to 2036. Clenpiq is a ready-to-drink, low‑volume bowel preparation with 2025 U.S. net sales of $20.6 million and broad payer coverage. The transaction is positioned by RedHill as completing a major strategic repositioning of its commercial gastrointestinal business.
RedHill Biopharma (NASDAQ: RDHL) has divested its Talicia business to a subsidiary of Apotex Health (TSX: APTX), converting its 70% stake into an $18 million upfront cash payment plus up to $35 million in potential worldwide net sales milestone payments.
According to RedHill, the transaction strengthens liquidity and is expected to fully fund the next major steps in expanding its U.S. gastrointestinal commercial franchise, including new FDA‑approved product opportunities. Apotex receives RedHill’s 70% interest in Talicia, after previously acquiring Cumberland Pharmaceuticals’ 30% ownership. RedHill highlights its late‑stage pipeline assets, including opaganib, RHB‑102 (Bekinda), RHB‑204 and RHB‑107, across gastrointestinal, infectious disease and oncology indications.
RedHill Biopharma (Nasdaq: RDHL) reported that confirmed Bundibugyo ebolavirus (BDBV) cases have risen to 3,221 with 1,407 deaths and outlined development progress for its investigational drug opaganib for Ebola virus disease. According to RedHill, discussions on next development steps and potential partnerships are ongoing with the African Medicines Agency Emergency Task Force, Uganda’s Ministry of Health, Mbarara University of Science and Technology, and the Democratic Republic of Congo Scientific Advisory Committee.
RedHill highlighted clinical data in severe COVID-19, where opaganib added to standard of care (including remdesivir) reduced mortality to 6.98% versus 23.4% on placebo and improved viral RNA clearance, with no additional safety signals in 470 participants. USAMRIID-funded preclinical studies showed Ebola inhibition in human macrophages, increased survival in one of two animal models, and synergy with remdesivir. Opaganib, an oral SPHK2 inhibitor with a host-directed mechanism, has prior U.S. BARDA selection for joint Ebola countermeasure development and is being developed across oncology, viral, inflammatory and metabolic indications. RedHill reaffirmed that opaganib remains investigational and is not approved or commercially available.
RedHill Biopharma (NASDAQ:CPIX) closed a private placement of 8,571,429 ADSs (or equivalents) plus series A-1 and A-2 warrants at a combined $0.70 per ADS. The deal provides about $6 million gross upfront, with up to $13.4 million additional potential proceeds from warrant exercises.
According to RedHill, funds are expected to support near-term liquidity and a possible acquisition of commercial-stage, revenue-generating pharmaceutical assets, though no definitive agreement exists and there is no assurance any acquisition or warrant exercise will occur.
RedHill Biopharma (CPIX) entered a definitive agreement for a private placement of 8,571,429 ADSs (or equivalents) plus series A-1 and A-2 warrants at a combined price of $0.70 per ADS. Gross proceeds are expected to be about $6 million, with up to $13.4 million more if all warrants are exercised.
The deal is expected to close on June 22, 2026. According to RedHill, proceeds will fund a potential strategic product acquisition and support working capital, R&D and general corporate purposes.
RedHill Biopharma (ticker: CPIX) announced that the FDA granted rare pediatric disease designation to opaganib for treating neuroblastoma, in addition to existing orphan drug designation.
Benefits may include a Priority Review Voucher, potential seven years' marketing exclusivity, fee waivers, tax credits and accelerated review, if approved.
RedHill Biopharma (Nasdaq:CPIX) has begun recognition and enforcement proceedings in Korea for a New York Supreme Court final judgment against Kukbo totaling about $10.9 million.
The judgment, including roughly $8.9 million principal and $1.95 million legal fees with 9% interest, is final and no longer appealable.
RedHill Biopharma (NASDAQ:CPIX) is pursuing collaborations, including with the WHO SOLIDARITY CORE platform, to clinically evaluate opaganib as a potential Ebola virus disease (EVD) treatment, targeting the Bundibugyo ebolavirus subtype.
According to RedHill, opaganib has Phase 3 antiviral data in severe COVID-19 and preclinical Ebola activity, but remains investigational and unapproved.
RedHill (CPIX) reported in vitro data showing its next-generation oral candidate RHB-204 demonstrates MAP killing comparable to RHB-104, achieved in spot and phage assays and using lower doses of two active ingredients. A Phase 2 trial in MAP-positive Crohn's disease patients is planned, with non-dilutive funding sought and multiple regulatory designations and patent protection through 2041.
RedHill Biopharma (Nasdaq: RDHL) reported full-year 2025 results and operational highlights on April 27, 2026, citing strategic transactions, commercial progress for Talicia and focused R&D activity. Key items include a $4.0M Cumberland investment into Talicia Holdings, Talicia U.S. net revenues of ~$8.9M, ex-U.S. revenues of ~$1.9M, a RHB-102 licensing deal worth up to $60M in milestones, a final $10.5M New York Supreme Court judgment in RedHill's favor, year-end cash of $4.1M and positive equity of $4.3M.